Alivus Life Sciences Ltd share price logo

Glenmark Life Sciences Share Price

NSE: ALIVUS

BSE: 543322

Small Cap

Healthcare Sector

₹939.00

+2.40

(+0.26%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Glenmark Life Sciences Stock Performance

as on September 17, 2025 at 4:01 pm IST

  • Day's Low

    Day's High

    ₹934.35
    ₹949
    downward going graph

    0.50%

    Downside

    1.06%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹850
    ₹1,335.1
    downward going graph

    9.48%

    Downside

    42.18%

    Upside

    downward going graph

Glenmark Life Sciences share price movements today

Previous Close
₹936.60
Open
₹936.60
Volume
98.22K
Upper Circuit
₹1,123.90
Lower Circuit
₹749.30
Day's Low - High
₹934.35 - ₹949
52 Week Low - High
₹850 - ₹1,335.1

Glenmark Life Sciences Historical Returns

1 Month Return
-2.04 %
3 Month Return
-7.54 %
1 Year Return
-28.53 %
3 Year Return
+ 127.25 %
5 Year Return
+ 25.13 %

Glenmark Life Sciences Fundamentals

as on September 17, 2025 at 4:01 pm IST

Market Cap

₹11,490.34 Cr

Return on Equity (ROE)

18.86

PE Ratio (TTM)

0

Return on capital employed (ROCE)

24.97

Beta (LTM)

0.7

P/B Ratio

4.7

Dividend Yield

0

PEG Ratio

0

Quarterly Earnings Growth YOY

9.02

EPS (TTM)

0

Sector

Pharmaceuticals

Book Value

0

Technical Analysis

Bearish

View Technical Analysis

Alivus Life Sciences Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Glenmark Life Sciences with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Alivus Life Sciences Ltd image
Alivus Life Sciences Ltd
BUY11,490.345.03%0.004852,386
Shilpa Medicare Ltd image
Shilpa Medicare Ltd
BUY8,080.468.35%0.60781,286
Decipher Labs Ltd image
Decipher Labs Ltd
NA10.41-10.65%0.50-235
Syncom Formulations (India) Ltd image
Syncom Formulations (India) Ltd
NA1,699.52192.71%0.5149465
Hester Biosciences Ltd image
Hester Biosciences Ltd
NA1,754.974.93%0.7428311
See all

Analyst Recommendation on Glenmark Life Sciences Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Glenmark Life Sciences. Average target price of ₹1266

Source: S&P Global Market Intelligence

Glenmark Life Sciences Share Price Target

Get share price movements and forecasts by analysts on Glenmark Life Sciences.

What analysts predicted

35.17%UPSIDE

Target Price

₹1266

Current Price

₹939

Analyzed by

4 Analysts

High

₹1382

Target

₹1266.00

Low

₹1150

Glenmark Life Sciences target price ₹1266, a slight upside of 35.17% compared to current price of ₹939. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Glenmark Life Sciences Stock's Interest Amongst Investors

Search interest for Alivus Life Sciences Ltd Stock has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-47% versus previous 30 day period

Alivus Life Sciences Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sales
509.3
540.73
621.32
578.45
595.36
572.8
536.6
588.62
506.88
641.84
649.55
601.85
Other Income
10.02
6.61
2.84
1.85
5.37
1.69
3.13
5.49
8.53
10.46
10.09
8.99
Total Income
519.32
547.34
624.16
580.3
600.73
574.5
539.73
594.11
515.41
652.3
659.63
610.83
Expenses
365.66
395.28
414.89
385.29
428.28
400.25
395.15
429.13
372.52
451.54
451.11
429.54
Operating Profit
143.64
145.45
206.43
193.16
167.08
172.55
141.45
159.49
134.36
190.3
198.44
172.31
Operating Profit Margin %
28.2%
26.9%
33.22%
33.39%
28.06%
30.12%
26.36%
27.1%
26.51%
29.65%
30.55%
28.63%
Profit Before Interest, Tax and Depreciation
153.66
152.06
209.27
195.01
172.45
174.25
144.58
164.98
142.89
200.76
208.52
181.3
Interest
0.13
0.16
0.12
0.4
0.4
0.39
0.36
0.35
0.34
0.46
1.26
1.25
Depreciation
9.94
10.76
11.52
12.61
13.13
13.18
14.53
14.39
15.09
15.16
15.97
17.06
Profit Before Tax
143.59
141.14
197.63
182
158.92
160.68
129.69
150.24
127.46
185.14
191.29
162.99
Tax Paid
36.71
36.15
51.27
46.56
40.19
41.92
31.74
38.76
32.14
48.19
49.43
41.45
Profit After Tax
106.88
104.99
146.36
135.45
118.74
118.77
97.94
111.48
95.32
136.96
141.87
121.54
Total Net profit including share of profit / Loss from associate company
106.88
104.99
146.36
135.45
118.74
118.77
97.94
111.48
95.32
136.96
141.87
121.54
EPS
8.72
8.57
11.94
11.05
9.69
9.69
7.99
9.1
7.78
11.18
11.57
9.91
Actual EPS
8.72
8.57
11.94
11.05
9.69
9.69
7.99
9.1
7.78
11.18
11.57
9.91
Adjusted EPS
8.72
8.57
11.94
11.05
9.69
9.69
7.99
9.1
7.78
11.18
11.57
9.91
Diluted EPS
8.72
8.57
11.94
11.05
9.69
9.67
7.97
9.08
7.75
11.14
11.55
9.88

Alivus Life Sciences Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2019
Mar 2020
Mar 2021
Sales
886.42
1,537.31
1,885.17
Other Income
0.44
11.99
0.81
Total Income
886.87
1,549.3
1,885.98
Expenses
638.7
1,065.35
1,294.09
Operating Profit
247.72
471.96
591.08
Operating Profit Margin %
27.95%
30.7%
31.35%
Profit Before Interest, Tax and Depreciation
248.16
483.95
591.89
Interest
0.61
33.52
87.55
Depreciation
19.26
29.37
33.39
Profit Before Tax
228.29
421.06
470.95
Tax Paid
32.71
107.97
119.37
Profit After Tax
195.59
313.1
351.58
Total Net profit including share of profit / Loss from associate company
195.59
313.1
351.58
EPS
24.64
29.04
32.61
Actual EPS
24.64
29.04
32.61
Adjusted EPS
0.45
0.53
2.96
Diluted EPS
24.64
29.04
32.61

Alivus Life Sciences Ltd Cash Flow

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
-0.48
10.35
195.01
388.11
597.59
306.01
413.52
391.52
Cash Flow from Investing Activities
-
-8.84
-50.52
-68.74
-122.22
-146.75
-116.48
-615.65
Cash Flow from Financing Activities
0.49
0.53
-136.55
-213.78
-78.8
-387.6
-279.45
-6.23
Net Cash Flow
0.01
2.05
7.94
105.6
396.56
-228.33
17.59
-230.35

Glenmark Life Sciences Stock Shareholding Pattern

Numbers in percentages

Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Promoters
82.85%
82.85%
82.85%
82.85%
82.85%
82.85%
82.85%
75%
75%
74.99%
74.94%
DII
0.09%
0%
0.58%
0.64%
0.59%
1.4%
1.57%
4.16%
4.86%
5.19%
5.61%
FII
0%
0%
0%
4.38%
0%
5.01%
4.82%
7.85%
6.74%
6.57%
6.42%
Public
12.6%
13.86%
13.3%
12.12%
11.84%
10.73%
10.76%
12.98%
13.4%
13.25%
13.03%
Total Outstanding Shares
12,25,27,172
12,25,27,172
12,25,27,172
12,25,27,172
12,25,27,172
12,25,27,172
12,25,27,172
12,25,28,672
12,25,32,862
12,25,37,052
12,26,29,148
Total Shareholders
2,25,730
2,22,866
2,08,267
1,98,764
1,85,531
1,56,183
1,49,396
1,43,960
1,46,840
1,41,977
1,38,500

Mutual Funds that own Glenmark Life Sciences Stock

Check out the Mutual Funds with significant holdings in Glenmark Life Sciences.

Glenmark Life Sciences Earnings and Dividends

View detailed summary of the earnings and dividend history of Glenmark Life Sciences.

  • Alivus Life Sciences Ltd Earnings Results

    Alivus Life Sciences Ltd’s net profit jumped 9.02% since last year same period to ₹121.54Cr in the Q1 2025-2026. On a quarterly growth basis, Alivus Life Sciences Ltd has generated -14.33% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Alivus Life Sciences Ltd Dividends May,2025

    In the quarter ending March 2025, Alivus Life Sciences Ltd has declared dividend of ₹5.00 per share on 15 May 2025 - translating a dividend yield of 0.53%.

    Read More about Dividends

Indices Featuring Glenmark Life Sciences Stock

Check stock indices that include Glenmark Life Sciences.

BSE Healthcare

₹44,738.73

-0.08 (▲-37.44%)

Nifty Smallcap 250

₹17,470.75

0.51 (▲88.55%)

Nifty MidSmallcap 400

₹20,277.15

0.3 (▲60.35%)

Nifty 500

₹23,445.20

0.32 (▲75.9%)

BSE Small-Cap

₹54,537.03

0.51 (▲276.99%)

Insights on Alivus Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 3.59% to 4.06% in Jun 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 138.8% return, outperforming this stock by 11.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 11.9% return, outperforming this stock by 40.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, ALIVUS stock has moved down by -8.4%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 74.99% to 74.94% in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 13.25% to 13.03% in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 6.57% to 6.42% in Jun 2025 quarter

About Alivus Life Sciences Ltd

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Revenue: ₹601.85Cr as on June 2025 (Q1 FY26)
Net Profit: ₹121.54Cr as on June 2025 (Q1 FY26)
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationAlivus Life Sciences Ltd
IndustryPharmaceuticals
CEOGlenn Saldanha
E-voting on sharesClick here to vote

FAQs

What is Glenmark Life Sciences share price today?

Glenmark Life Sciences share price today stands at ₹939 as on at the close of the market. Glenmark Life Sciences share today touched a day high of ₹949 and a low of ₹934.35.

What is the 52 week high and 52 week low range for Glenmark Life Sciences share?

Glenmark Life Sciences touched a 52 week high of ₹1335.1 and a 52 week low of ₹850. Glenmark Life Sciences share price today i.e. is closed at ₹939, which is -29.67% down from its 52 week high and 10.47% up from its 52 week low.

What is Glenmark Life Sciences's market capitalisation today?

Glenmark Life Sciences market capitalisation is ₹11,490.34 Cr as on .

How to buy Glenmark Life Sciences shares?

To buy Glenmark Life Sciences shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for ALIVUS or Alivus Life Sciences Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Glenmark Life Sciences shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Glenmark Life Sciences trading volume today?

Glenmark Life Sciences trading volume is 98.22K as on . This means that 98.22K shares of Glenmark Life Sciences were bought and sold on the stock market during today's trading session.